AnaptysBio's lead candidate shows positive effect in mid-stage peanut allergy study; shares ahead 7% after hours [Seeking Alpha]
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: Seeking Alpha
AnaptysBio's lead candidate shows positive effect in mid-stage peanut allergy study; shares ahead 7% after hoursAnaptysBio (NASDAQ:ANAB) is up7% after hours on the heels of itsannouncement of positive preliminary results from a Phase 2a proof-of-concept clinical trial assessing lead drug ANB020 in adult patients with peanut allergy.After a single intravenous dose of ANB020 46% (n=6/13) patients exhibiting moderate-to-severe symptoms during a baseline oral food challenge at enrollment improved peanut tolerance to a cumulative 500 mg at day 14 compared to 0% (n=0/3) for placebo.Detailed data will be submitted for presentation at a future medical conference.ANB020 is an antibody that binds to the pro-inflammatory cytokine interleukin 33 (IL-33), a protein that plays a key role in atopic diseases, including asthma, food allergies and atopic dermatitis.Management will host a conference call today at 5:00 pm ET to discuss the results.Previously:AnaptysBio's lead candidate ANB020 shows treat
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- Industry Analysts Just Made A Stunning Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts [Yahoo! Finance]Yahoo! Finance
- Jemperli Cancer Drug: What To Know As GSK Says It Improves Survival For Uterine Cancer Patients [Forbes]Forbes
- Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer [Yahoo! Finance]Yahoo! Finance
- AnaptysBio, Inc. (NASDAQ: ANAB) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $34.00 price target on the stock, up previously from $20.00.MarketBeat
- Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
ANAB
Earnings
- 3/11/24 - Beat
ANAB
Sec Filings
- 3/26/24 - Form 4
- 3/11/24 - Form S-8
- 3/11/24 - Form 10-K
- ANAB's page on the SEC website